Cargando…

Pharmacokinetics of β-Alanine Using Different Dosing Strategies

Introduction: The ergogenic response following long-term ingestion of β-alanine shows a high inter-individual variation. It is hypothesized that this variation is partially caused by a variable pharmacokinetic response induced by inferior dosing strategies. At this point most supplements are either...

Descripción completa

Detalles Bibliográficos
Autores principales: Stautemas, Jan, Everaert, Inge, Lefevere, Filip B. D., Derave, Wim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107792/
https://www.ncbi.nlm.nih.gov/pubmed/30175101
http://dx.doi.org/10.3389/fnut.2018.00070
_version_ 1783350029367377920
author Stautemas, Jan
Everaert, Inge
Lefevere, Filip B. D.
Derave, Wim
author_facet Stautemas, Jan
Everaert, Inge
Lefevere, Filip B. D.
Derave, Wim
author_sort Stautemas, Jan
collection PubMed
description Introduction: The ergogenic response following long-term ingestion of β-alanine shows a high inter-individual variation. It is hypothesized that this variation is partially caused by a variable pharmacokinetic response induced by inferior dosing strategies. At this point most supplements are either taken in a fixed amount (× g), as is the case with β-alanine, or relative to body weight (× g per kg BW), but there is currently neither consensus nor a scientific rationale on why these or other dosing strategies should be used. The aim of this study is to objectify and understand the variation in plasma pharmacokinetics of a single oral β-alanine dose supplemented as either a fixed or a weight-relative dose (WRD) in an anthropometric diverse sample. Methods: An anthropometric diverse sample ingested a fixed dose (1,400 mg) (n = 28) and a WRD of β-alanine (10 mg/kg BW) (n = 34) on separate occasions. Blood samples were taken before and at nine time points (up to 4 h) after β-alanine ingestion in order to establish a pharmacokinetic profile. Incremental area under the curve (iAUC) was calculated by the trapezoidal rule. Plasma β-alanine was quantified using HPLC-fluorescence. Results: The variation coefficient (CV%) of the iAUC was 35.0% following ingestion of 1,400 mg β-alanine. Body weight explained 30.1% of the variance and was negatively correlated to iAUC (r = −0.549; p = 0.003). Interestingly, the CV% did not decrease with WRD (33.2%) and body weight was positively correlated to iAUC in response to the WRD (r = 0.488; p = 0.003). Conclusion: Both dosing strategies evoked an equally high inter-individual variability in pharmacokinetic plasma profile. Strikingly, while body weight explained a relevant part of the variation observed following a fixed dose, correction for body weight did not improve the homogeneity in β-alanine plasma response. We suggest to put more effort into the optimization of easy applicable and scientifically justified personalized dosing strategies.
format Online
Article
Text
id pubmed-6107792
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61077922018-08-31 Pharmacokinetics of β-Alanine Using Different Dosing Strategies Stautemas, Jan Everaert, Inge Lefevere, Filip B. D. Derave, Wim Front Nutr Nutrition Introduction: The ergogenic response following long-term ingestion of β-alanine shows a high inter-individual variation. It is hypothesized that this variation is partially caused by a variable pharmacokinetic response induced by inferior dosing strategies. At this point most supplements are either taken in a fixed amount (× g), as is the case with β-alanine, or relative to body weight (× g per kg BW), but there is currently neither consensus nor a scientific rationale on why these or other dosing strategies should be used. The aim of this study is to objectify and understand the variation in plasma pharmacokinetics of a single oral β-alanine dose supplemented as either a fixed or a weight-relative dose (WRD) in an anthropometric diverse sample. Methods: An anthropometric diverse sample ingested a fixed dose (1,400 mg) (n = 28) and a WRD of β-alanine (10 mg/kg BW) (n = 34) on separate occasions. Blood samples were taken before and at nine time points (up to 4 h) after β-alanine ingestion in order to establish a pharmacokinetic profile. Incremental area under the curve (iAUC) was calculated by the trapezoidal rule. Plasma β-alanine was quantified using HPLC-fluorescence. Results: The variation coefficient (CV%) of the iAUC was 35.0% following ingestion of 1,400 mg β-alanine. Body weight explained 30.1% of the variance and was negatively correlated to iAUC (r = −0.549; p = 0.003). Interestingly, the CV% did not decrease with WRD (33.2%) and body weight was positively correlated to iAUC in response to the WRD (r = 0.488; p = 0.003). Conclusion: Both dosing strategies evoked an equally high inter-individual variability in pharmacokinetic plasma profile. Strikingly, while body weight explained a relevant part of the variation observed following a fixed dose, correction for body weight did not improve the homogeneity in β-alanine plasma response. We suggest to put more effort into the optimization of easy applicable and scientifically justified personalized dosing strategies. Frontiers Media S.A. 2018-08-17 /pmc/articles/PMC6107792/ /pubmed/30175101 http://dx.doi.org/10.3389/fnut.2018.00070 Text en Copyright © 2018 Stautemas, Everaert, Lefevere and Derave. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Stautemas, Jan
Everaert, Inge
Lefevere, Filip B. D.
Derave, Wim
Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_full Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_fullStr Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_full_unstemmed Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_short Pharmacokinetics of β-Alanine Using Different Dosing Strategies
title_sort pharmacokinetics of β-alanine using different dosing strategies
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107792/
https://www.ncbi.nlm.nih.gov/pubmed/30175101
http://dx.doi.org/10.3389/fnut.2018.00070
work_keys_str_mv AT stautemasjan pharmacokineticsofbalanineusingdifferentdosingstrategies
AT everaertinge pharmacokineticsofbalanineusingdifferentdosingstrategies
AT lefeverefilipbd pharmacokineticsofbalanineusingdifferentdosingstrategies
AT deravewim pharmacokineticsofbalanineusingdifferentdosingstrategies